Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

MLA

Wu, Yi-Long, et al. “Intercalated Combination of Chemotherapy and Erlotinib for Patients with Advanced Stage Non-Small-Cell Lung Cancer (FASTACT-2): A Randomised, Double-Blind Trial.” Lancet Oncology, vol. 14, no. 8, July 2013, pp. 777–86. EBSCOhost, https://doi.org/10.1016/S1470-2045(13)70254-7.

APA

Wu, Y.-L., Lee, J. S., Thongprasert, S., Yu, C.-J., Zhang, L., Ladrera, G., Srimuninnimit, V., Sriuranpong, V., Sandoval-Tan, J., Zhu, Y., Liao, M., Zhou, C., Pan, H., Lee, V., Chen, Y.-M., Sun, Y., Margono, B., Fuerte, F., Chang, G.-C., & Seetalarom, K. (2013). Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncology, 14(8), 777–786. https://doi.org/10.1016/S1470-2045(13)70254-7

Chicago

Wu, Yi-Long, Jin Soo Lee, Sumitra Thongprasert, Chong-Jen Yu, Li Zhang, Guia Ladrera, Vichien Srimuninnimit, et al. 2013. “Intercalated Combination of Chemotherapy and Erlotinib for Patients with Advanced Stage Non-Small-Cell Lung Cancer (FASTACT-2): A Randomised, Double-Blind Trial.” Lancet Oncology 14 (8): 777–86. doi:10.1016/S1470-2045(13)70254-7.